Dr. Centor discusses the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in the treatment of patients with type 2 diabetes with Drs. Neda Laiteerapong and Aaron Winn.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
